

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

These are multidose vials which contain 8 doses or 10 doses of 0.5 mL per vial (see section 6.5).

One dose (0.5 mL) contains:

Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S)*, not less than 2.5×10^8 infectious units (Inf.U)

*Produced in genetically modified human embryonic kidney (HEK) 293 cells and by recombinant DNA technology.

This product contains genetically modified organisms (GMOs).

Excipient with known effect

Each dose (0.5 mL) contains approximately 2 mg of ethanol.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Suspension for injection (injection).

The suspension is colourless to slightly brown, clear to slightly opaque with a pH of 6.6.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Vaxzevria is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

The use of this vaccine should be in accordance with official recommendations.

4.2 Posology and method of administration

Posology

Individuals 18 years of age and older

The Vaxzevria vaccination course consists of two separate doses of 0.5 mL each. The second dose should be administered between 4 and 12 weeks (28 to 84 days) after the first dose (see section 5.1).

There are no data available on the interchangeability of Vaxzevria with other COVID-19 vaccines to complete the vaccination course. Individuals who have received the first dose of Vaxzevria should receive the second dose of Vaxzevria to complete the vaccination course.

Elderly population

No dose adjustment is required. See also section 5.1.

Paediatric population

The safety and efficacy of Vaxzevria in children and adolescents (less than 18 years of age) have not yet been established. No data are available.

Method of administration

Vaxzevria is for intramuscular injection only, preferably in the deltoid muscle of the upper arm.

Do not inject the vaccine intravascularly, subcutaneously or intradermally.

The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products.

For precautions to be taken before administering the vaccine, see section 4.4.

For instructions on handling and disposal, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Individuals who have experienced thrombosis with thrombocytopenia syndrome (TTS) following vaccination with Vaxzevria (see section 4.2).

Individuals who have previously experienced episodes of capillary leak syndrome (see also section 4.4).

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity and anaphylaxis

Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. Close observation for at least 15 minutes is recommended following vaccination. A second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Vaxzevria.

Anxiety-related reactions

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.

Concurrent illness

Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. However, the presence of a minor infection and/or low-grade fever should not delay vaccination.

Coagulation disorders

Thrombosis with thrombocytopenia syndrome

Thrombosis with thrombocytopenia syndrome (TTS), in some cases accompanied by bleeding, has been observed very rarely following vaccination with Vaxzevria. This includes severe cases presenting as venous thrombosis, including unusual sites such as cerebral venous sinus thrombosis, splanchnic vein thrombosis, as well as arterial thrombosis, concomitant with thrombocytopenia. Some cases had a fatal outcome. The majority of these cases occurred within the first three weeks following vaccination.

Thrombocytopenia

Cases of thrombocytopenia, including immune thrombocytopenia (ITP), have been reported after receiving Vaxzevria, typically within the first four weeks after vaccination. Very rarely, these presented with very low platelet levels (<20,000 per μL) and/or were associated with bleeding. Some of these cases occurred in individuals with a history of immune thrombocytopenia. Cases with fatal outcome have been reported. If an individual has a history of a thrombocytopenic disorder, such as immune thrombocytopenia, the risk of developing low platelet levels should be considered before administering the vaccine and platelet monitoring is recommended after vaccination.

Healthcare professionals should be alert to the signs and symptoms of thromboembolism and/or thrombocytopenia. Those vaccinated should be instructed to seek immediate medical attention if they develop symptoms such as shortness of breath, chest pain, leg swelling, leg pain, persistent abdominal pain following vaccination. Additionally, anyone with neurological symptoms including severe or persistent headaches, blurred vision, confusion or seizures after vaccination, or who experiences spontaneous bleeding, skin bruising (petechia) beyond the site of vaccination after a few days, should seek prompt medical attention.

Individuals diagnosed with thrombocytopenia within three weeks after vaccination with Vaxzevria, should be actively investigated for signs of thrombosis. Similarly, individuals who present with thrombosis within three weeks of vaccination should be evaluated for thrombocytopenia.

TTS requires specialised clinical management. Healthcare professionals should consult applicable guidance and/or consult specialists (e.g., haematologists, specialists in coagulation) to diagnose and treat this condition.

Risk of bleeding with intramuscular administration

As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.

Capillary leak syndrome

Very rare cases of capillary leak syndrome (CLS) have been reported in the first days after vaccination with Vaxzevria. A history of CLS was apparent in some of the cases. Fatal outcome has been reported. CLS is a rare disorder characterised by acute episodes of oedema mainly affecting the limbs, hypotension, haemoconcentration and hypoalbuminaemia. Patients with an acute episode of CLS following vaccination require prompt recognition and treatment. Intensive supportive therapy is usually warranted. Individuals with a known history of CLS should not be vaccinated with this vaccine. See also section 4.3.

Neurological events

Guillain-Barré syndrome (GBS) has been reported very rarely following vaccination with Vaxzevria. Healthcare professionals should be alert of GBS signs and symptoms to ensure correct diagnosis, in order to initiate adequate supportive care and treatment, and to rule out other causes.

Immunocompromised individuals

The efficacy, safety and immunogenicity of the vaccine have not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of Vaxzevria may be lower in immunosuppressed individuals.

Duration of protection

The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials.

Limitations of vaccine effectiveness

Protection starts from approximately 3 weeks after the first dose of Vaxzevria. Individuals may not be fully protected until 15 days after the second dose is administered. As with all vaccines, vaccination with Vaxzevria may not protect all vaccine recipients (see section 5.1).

Excipients

Sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per 0.5 mL dose, that is to say essentially “sodium-free”.

Ethanol

This medicinal product contains 2 mg of alcohol (ethanol) per 0.5 mL dose. The small amount of alcohol in this medicinal product will not have any noticeable effects.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Concomitant administration of Vaxzevria with other vaccines has not been studied.

4.6 Fertility, pregnancy and lactation

Pregnancy

There is limited experience with use of Vaxzevria in pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/foetal development, parturition or post-natal development (see section 5.3).

Administration of Vaxzevria during pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and fetus.

Breastfeeding

It is unknown whether Vaxzevria is excreted in human milk.

In animal studies, lactational transfer of anti-SARS-CoV-2 S antibodies from maternal female mice to pups was observed (see section 5.3).

Fertility

Animal studies do not indicate direct or indirect harmful effects with respect to fertility (see section 5.3).

4.7 Effects on ability to drive and use machines

Vaxzevria has no or negligible influence on the ability to drive and use machines. However, some of the adverse reactions mentioned under section 4.8 may temporarily affect the ability to drive or use machines.

4.8 Undesirable effects

Summary of the safety profile

The overall safety of Vaxzevria is based on an analysis of pooled data from four clinical trials phase I/II, II/III and III conducted in the United Kingdom, Brazil, and South Africa, and of data from an additional phase III clinical trial conducted in the United States, Peru and Chile. At the time of the analysis, a total of 56,124 participants ≥ 18 years old had been randomised and of these, 33,869 received at least one dose of Vaxzevria and 31,217 received two doses.

The most frequently reported adverse reactions are injection site tenderness (68%), injection site pain (58%), headache (53%), fatigue (53%), myalgia (44%), malaise (44%), pyrexia (includes feverishness [33%] and fever $\geq 38^{\circ}\text{C}$ [8%]), chills (32%), arthralgia (27%) and nausea (22%). The majority of these adverse reactions were mild to moderate in severity and usually resolved within a few days of vaccination.

Very rare cases of thrombosis with thrombocytopenia syndrome have been reported post-marketing within the first three weeks following vaccination (see section 4.4).

Following vaccination with Vaxzevria, recipients may experience multiple adverse reactions occurring at the same time (for example, myalgia/arthralgia, headache, chills, pyrexia and malaise).

When compared with the first dose, adverse reactions reported after the second dose were milder and less frequent.

Reactogenicity was generally milder and reported less frequently in the population of older adults (≥ 65 years old).

The safety profile was consistent across participants with or without prior evidence of SARS-CoV-2 infection at baseline.

Tabulated list of adverse reactions

The safety profile presented below is based on an analysis of data from five clinical trials which included participants ≥ 18 years old (pooled data from four clinical trials conducted in the United Kingdom, Brazil and South Africa, and data from one clinical trial conducted in the United States, Peru and Chile) and on data from post-authorisation experience.

Adverse drug reactions (ADRs) are organised by MedDRA System Organ Class (SOC). Frequencies of occurrence of adverse reactions are defined as: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1,000$ to $< 1/100$); rare ($\geq 1/10,000$ to $< 1/1,000$); very rare ($< 1/10,000$) and not known (cannot be estimated from available data); within each SOC, preferred terms are arranged by decreasing frequency and then by decreasing seriousness.

Table 1 Adverse drug reactions

MedDRA SOC	Frequency	Adverse Reactions
Blood and lymphatic system disorders	Common	Thrombocytopenia ^a
	Uncommon	Lymphadenopathy
	Not known	Immune thrombocytopenia ^b
Immune system disorders	Not known	Anaphylaxis Hypersensitivity

MedDRA SOC	Frequency	Adverse Reactions
Metabolism and nutrition disorders	Uncommon	Decreased appetite
Nervous system disorders	Very common	Headache ^c
	Uncommon	Dizziness Somnolence Lethargy
	Rare	Facial paralysis ^d
	Very rare	Guillain-Barré syndrome
Vascular disorders	Very rare	Thrombosis with thrombocytopenia syndrome ^e
	Not known	Capillary leak syndrome
Gastrointestinal disorders	Very common	Nausea
	Common	Vomiting Diarrhoea
	Uncommon	Abdominal pain
Skin and subcutaneous tissue disorders	Uncommon	Hyperhidrosis Pruritus Rash Urticaria
	Not known	Angioedema
Musculoskeletal and connective tissue disorders	Very common	Myalgia Arthralgia
	Common	Pain in extremity
	Uncommon	Muscle spasms
General disorders and administration site conditions	Very common	Injection site tenderness, pain, warmth, pruritus, bruising ^f Fatigue Malaise Feverishness Chills
	Common	Injection site swelling, erythema Fever ^g Influenza-like illness Asthenia

^a In clinical trials, transient mild thrombocytopenia was commonly reported (see section 4.4).

^b Cases have been reported post-marketing (see also section 4.4).

^c Headache includes migraine (uncommon).

^d Based on data from the clinical trial conducted in the United States, Peru and Chile. Through the safety follow-up period to 05 March 2021, facial paralysis (or palsy) was reported by five participants in the Vaxzevria group. Onset was 8 and 15 days after first dose and 4, 17, and 25 days after the second dose. All events were reported to be non-serious. No cases of facial paralysis were reported in the placebo group.

^e Severe and very rare cases of thrombosis with thrombocytopenia syndrome have been reported post-marketing. These included venous thrombosis such as cerebral venous sinus thrombosis, splanchnic vein thrombosis, as well as arterial thrombosis (see section 4.4).

^f Injection site bruising includes injection site haematoma (uncommon).

^g Measured fever $\geq 38^{\circ}\text{C}$.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via **the national reporting system** listed in [Appendix V](#) and include batch/Lot number if available.

4.9 Overdose

There is no specific treatment for an overdose with Vaxzevria. In the event of an overdose, the individual should be monitored and provided with symptomatic treatment as appropriate.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Vaccines, other viral vaccines, ATC code: J07BX03

Mechanism of action

Vaxzevria is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector encoding the S glycoprotein of SARS-CoV-2. The SARS-CoV-2 S immunogen in the vaccine is expressed in the trimeric pre-fusion conformation; the coding sequence has not been modified in order to stabilise the expressed S-protein in the pre-fusion conformation. Following administration, the S glycoprotein of SARS-CoV-2 is expressed locally stimulating neutralising antibody and cellular immune responses, which may contribute to protection to COVID-19.

Clinical efficacy

Analysis of data from Study D8110C00001

The clinical efficacy of Vaxzevria has been evaluated based on an analysis of Study D8110C00001: a randomised, double-blinded, placebo-controlled phase III study conducted in the United States, Peru and Chile. The study excluded participants with severe and/or uncontrolled cardiovascular, gastrointestinal, liver, renal, endocrine/metabolic disease, and neurological illnesses; as well as those with severe immunosuppression, pregnant women and participants with a known history of SARS-CoV-2 infection. All participants are planned to be followed for up to 12 months, for assessments of efficacy against COVID-19 disease.

Participants ≥ 18 years of age received two doses (5×10^{10} viral particles per dose corresponding to not less than 2.5×10^8 infectious units) of Vaxzevria (N=17,662) or saline placebo (N=8,550), administered via IM injection on Day 1 and Day 29 (-3 to +7 days). The median dose interval was 29 days and the majority of participants (95.7% and 95.3% for Vaxzevria and placebo, respectively) received the second dose ≥ 26 to ≤ 36 days after dose 1.

Baseline demographics were well balanced across the Vaxzevria and placebo groups. Of the participants who received Vaxzevria, 79.1% were aged 18 to 64 years (with 20.9% aged 65 or older) and 43.8% of subjects were female. Of those randomised, 79.3% were White, 7.9% were Black, 4.2% were Asian, 4.2% were American Indian or Alaska Native. A total of 10,376 (58.8%) participants had at least one pre-existing comorbidity, defined as: chronic kidney disease, chronic obstructive pulmonary disease, lower immune health because of a solid organ transplant, history of obesity (BMI >30), serious heart conditions, sickle cell disease, type 1 or 2 diabetes, asthma, dementia, cerebrovascular diseases, cystic fibrosis, high blood pressure, liver disease, pulmonary fibrosis, thalassemia or history of smoking. At the time of analysis the median follow-up time post-dose 2 was 61 days.

Final determination of COVID-19 cases were made by an adjudication committee. Overall vaccine efficacy and efficacy by key age groups are presented in Table 2.

Table 2 – Vaxzevria efficacy against symptomatic COVID-19 illness in Study D8110C00001

	Vaxzevria			Placebo			Vaccine efficacy % (95% CI) ^b
	N	Number of COVID-19 cases ^a , n (%)	Incidence rate of COVID-19 per 1,000 person-years	N	Number of COVID-19 cases ^a , n (%)	Incidence rate of COVID-19 per 1,000 person-years	
Overall (age ≥18 years old)	17,662	73 (0.4)	35.69	8,550	130 (1.5)	137.23	74.0 (65.3, 80.5)
Age 18 to 64 years old	13,966	68 (0.5)	40.47	6,738	116 (1.7)	148.99	72.8 (63.4, 79.9)
Age ≥65 years old	3,696	5 (0.1)	13.69	1,812	14 (0.8)	82.98	83.5 (54.2, 94.1)

N = Number of subjects included in each group; n = Number of subjects having a confirmed event; CI = Confidence Interval.

^a Symptomatic COVID-19 requiring positive Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) and at least 1 respiratory sign or symptom, or at least 2 other systemic signs or symptoms, as defined in the protocol.

^b The confidence intervals were not adjusted for multiplicity.

Severe or critical symptomatic COVID-19 illness was assessed as a key secondary endpoint. Among all subjects in the per protocol set, no cases of severe or critical symptomatic COVID-19 were reported in the vaccine group compared with 8 cases reported in the placebo group. There were 9 hospitalised cases, the 8 cases that were adjudicated as severe or critical symptomatic COVID-19, and one additional case in the vaccine group. The majority of the severe or critical symptomatic COVID-19 cases fulfilled only the oxygen saturation (SpO₂) criterion for severe disease ($\leq 93\%$ on room air).

In individuals with or without prior evidence of SARS-CoV-2 infection, the vaccine efficacy of Vaxzevria (≥ 15 days post-dose 2) was 73.7% (95% CI: 63.1; 80.1); 76 (0.4%) vs 135 (1.5%) cases of COVID-19 for Vaxzevria (N=18,563) and placebo (N=9,031), respectively.

Participants with one or more comorbidities who received Vaxzevria (≥ 15 days post-dose 2) had an efficacy of 75.2% (95% CI: 64.2; 82.9) and participants without comorbidities had a vaccine efficacy of 71.8% (95% CI: 55.5, 82.1).

Analysis of pooled data from COV002 and COV003

The clinical efficacy of Vaxzevria has been evaluated based on an analysis of pooled data from two on-going randomised, blinded, controlled trials: a phase II/III study, COV002, in adults ≥ 18 years of age (including the elderly) in the UK; and a phase III study, COV003, in adults ≥ 18 years of age (including the elderly) in Brazil. The studies excluded participants with severe and/or uncontrolled cardiovascular, gastrointestinal, liver, renal, endocrine/metabolic disease, and neurological illnesses; as well as those with severe immunosuppression, pregnant women and participants with a known history of SARS-CoV-2 infection. Influenza vaccines could be administered 7 days before or after any dose of Vaxzevria. All participants are planned to be followed for up to 12 months, for assessments of safety and efficacy against COVID-19 disease.

In the pooled analysis for efficacy, participants ≥ 18 years of age received two doses (5×10^{10} viral particles per dose corresponding to not less than 2.5×10^8 infectious units) of Vaxzevria (N=6,106) or control (meningococcal vaccine or saline) (N=6,090), administered via IM injection.

Because of logistical constraints, the interval between dose 1 and dose 2 ranged from 3 to 23 weeks (21 to 159 days), with 86.1% of participants receiving their two doses within the interval of 4 to 12 weeks (28 to 84 days).

Baseline demographics were well balanced across Vaxzevria and control treatment groups. In the pooled analysis, among the participants who received Vaxzevria with a dose interval of between 4 and 12 weeks, 87.0% of participants were 18 to 64 years old (with 13.0% aged 65 or older and 2.8% aged 75 or older); 55.1% of subjects were female; 76.2% were White, 6.4% were Black and 3.4% were Asian. A total of 2,068 (39.3%) participants had at least one pre-existing comorbidity (defined as a BMI ≥ 30 kg/m², cardiovascular disorder, respiratory disease or diabetes). At the time of analysis the median follow-up time post-dose 2 was 78 days.

Final determination of COVID-19 cases were made by an adjudication committee, who also assigned disease severity according to the WHO clinical progression scale. A total of 218 participants had SARS-CoV-2 virologically confirmed COVID-19 occurring ≥ 15 days post second dose with at least one COVID-19 symptom (objective fever (defined as $\geq 37.8^\circ\text{C}$), cough, shortness of breath, anosmia, or ageusia) and were without evidence of previous SARS-CoV-2 infection. Vaxzevria significantly decreased the incidence of COVID-19 compared to control (see Table 3).

Table 3 Vaxzevria efficacy against COVID-19 from COV002 and COV003^a

Population	Vaxzevria		Control		Vaccine efficacy % (95% CI) ^b
	N	Number of COVID-19 cases, n (%)	N	Number of COVID-19 cases, n (%)	
Licensing regimen					
4 – 12 weeks (28 to 84 days)	5,258	64 (1.2)	5,210	154 (3.0)	59.5 (45.8, 69.7)

N = Number of subjects included in each group; n = Number of subjects having a confirmed event; CI = Confidence Interval;

^a Efficacy endpoint was based on confirmed COVID-19 cases in subjects aged 18 years and over who were seronegative at baseline, who had received two doses and were on-study ≥ 15 days post second dose.

^b CI not adjusted for multiplicity.

Vaccine efficacy was 62.6% (95% CI: 50.9; 71.5) in participants receiving two recommended doses with any dose interval (ranging from 3 to 23 weeks), in a pre-specified analysis.

Regarding COVID-19 hospitalisation (WHO Severity grading ≥ 4) there were 0 (0.0%; N=5,258) cases of COVID-19 hospitalisation in participants who received two doses of Vaxzevria (≥ 15 days post-dose 2) as compared to 8 (0.2%; N=5,210) for control, including one severe case (WHO Severity grading ≥ 6), reported for control. In all participants who received at least one dose, as from 22 days post-dose 1, there were 0 (0.0%, N=8,032) cases of COVID-19 hospitalisation in participants who received Vaxzevria, as compared to 14 (0.2%, N=8,026), including one fatality, reported for control.

Participants who had one or more comorbidities had a vaccine efficacy of 58.3% (95% CI: 33.6; 73.9); 25 (1.2%) vs 60 (2.9%) cases of COVID-19 for Vaxzevria (N=2,068) and control (N=2,040), respectively; which was similar to the vaccine efficacy observed in the overall population.

Evidence shows protection starts from approximately 3 weeks after first dose of vaccine. A second dose should be given at a 4 to 12-week interval after the first dose (see section 4.4).

Elderly population

Study D8110C00001 assessed the efficacy of Vaxzevria in 5,508 individuals ≥ 65 years of age; 3,696 who received Vaxzevria and 1,812 who received placebo. The efficacy of Vaxzevria was consistent between elderly (≥ 65 years) and younger adult subjects (18-64 years).

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Vaxzevria in one or more subsets of the paediatric population in prevention of COVID-19 (see section 4.2 for information on paediatric use).

Conditional approval

This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. This means that further evidence on this medicinal product is awaited.

The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.

5.2 Pharmacokinetic properties

Not applicable.

5.3 Preclinical safety data

In a repeat-dose toxicity study in mice, IM administration of Vaxzevria was well tolerated. Non-adverse, mixed and/or mononuclear cell inflammation was observed in the subcutaneous tissues and skeletal muscle of the administration sites and adjacent sciatic nerve consistent with the anticipated findings after IM injection of vaccines. There were no findings in the administration sites or sciatic nerves at the end of the recovery period, indicating complete recovery of the Vaxzevria-related inflammation.

Genotoxicity/Carcinogenicity

Neither genotoxicity nor carcinogenicity studies were performed. The components of the vaccine are not expected to have genotoxic potential.

Reproductive toxicity

In a reproductive and development toxicity study, Vaxzevria did not induce maternal or developmental toxicity following maternal exposure during the pre-mating, gestation or lactating periods. In this study, vaccine elicited detectable anti-SARS-CoV-2 S-glycoprotein maternal antibodies were transferred to the foetuses and pups, indicating placental and lactational transfer, respectively. No Vaxzevria data are available on vaccine excretion in milk.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

L-Histidine
L-Histidine hydrochloride monohydrate
Magnesium chloride hexahydrate
Polysorbate 80 (E 433)
Ethanol
Sucrose
Sodium chloride
Disodium edetate (dihydrate)
Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products or diluted.

6.3 Shelf life

Unopened vial

6 months when stored in a refrigerator (2°C – 8°C)

The following information is intended to guide healthcare professionals only in case of an unforeseen temporary temperature excursion. It is not a recommended storage or shipping condition.

The shelf-life of unopened vials includes the following unforeseen excursions from refrigerated storage (2°C – 8°C) for a single period of:

- 12 hours up to 30°C
- 72 hours down to -3°C

Unopened vials must always be returned to refrigerated storage (2°C – 8°C) following a temperature excursion.

The occurrence of a temperature excursion for unopened vials does not impact how the vials should be stored after first opening (first vial puncture).

Opened vial

Chemical and physical in-use stability have been demonstrated for 6 hours when stored at temperatures up to 30°C and for 48 hours when stored in a refrigerator (2°C – 8°C). After this time, the vial must be discarded. Do not return it to the refrigerator after storage outside the refrigerator.

Alternatively, an opened vial may be stored in a refrigerator (2°C – 8°C) for a maximum of 48 hours if it is immediately returned to the refrigerator following each puncture.

From a microbiological point of view, after first opening the vaccine should be used immediately. If the vaccine is not used immediately, in-use storage times and conditions are the responsibility of the user.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Keep vials in outer carton in order to protect from light.

For storage conditions after first opening of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Multidose vial

8-dose vial

4 mL of suspension in an 8-dose vial (clear type I glass) with stopper (elastomeric with aluminium overseal). Each vial contains 8 doses of 0.5 mL. Pack sizes of 10 multidose vials.

10-dose vial

5 mL of suspension in a 10-dose vial (clear type I glass) with stopper (elastomeric with aluminium overseal). Each vial contains 10 doses of 0.5 mL. Pack sizes of 10 multidose vials.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Handling instructions and administration

This vaccine should be handled by a healthcare professional using aseptic technique to ensure the sterility of each dose.

Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Unopened multidose vial should be stored in a refrigerator (2°C – 8°C). Do not freeze.

Keep the vials in outer carton in order to protect from light.

The vaccine should be inspected visually for particulate matter and discolouration prior to administration. Vaxzevria is a colourless to slightly brown, clear to slightly opaque suspension. Discard the vial if the suspension is discoloured or visible particles are observed. Do not shake. Do not dilute the suspension.

The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products.

The Vaxzevria vaccination course consists of two separate doses of 0.5 mL each. The second dose should be administered between 4 and 12 weeks after the first dose. Individuals who have received the first dose of Vaxzevria should receive the second dose of the same vaccine to complete the vaccination course.

Each vaccine dose of 0.5 mL is withdrawn into a syringe for injection to be administered intramuscularly, preferably in the deltoid muscle of the upper arm. Use a new needle for administration, when possible.

It is normal for liquid to remain in the vial after withdrawing the final dose. An additional overfill is included in each vial to ensure that 8 doses (vial of 4 mL) or 10 doses (vial of 5 mL) of 0.5 mL can be delivered. Do not pool excess vaccine from multiple vials. Discard any unused vaccine.

From the time of vial opening (first needle puncture) use within 6 hours when stored at temperatures up to 30°C. After this time, the vial must be discarded. Do not return it to the refrigerator. Alternatively, an opened vial may be stored in a refrigerator (2°C – 8°C) for a maximum of 48 hours if it is immediately returned to the refrigerator following each puncture.

Disposal

Any unused vaccine or waste material should be disposed of in compliance with the local guidance for pharmaceutical waste. Potential spills should be disinfected using agents with viricidal activity against adenovirus.

7. MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/21/1529/001 10 multidose vials (8 doses per vial)
EU/1/21/1529/002 10 multidose vials (10 doses per vial)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 29 January 2021

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>

ANNEX II

- A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**
- E. SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION**

**A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer(s) of the biological active substance

Henogen S.A.
Rue de la Marlette 14
7180 Seneffe
Belgium

Catalent Maryland, Inc
7555 Harmans Road
Harmans, MD 21077
United States

Oxford Biomedica (UK) Limited
Unit A
Plot 7000
Alec Issigonis Way
Oxford OX4 2ZY
United Kingdom

Halix B.V.
Tinbergenweg 1
2333 BB Leiden
Netherlands

SK Bioscience Co Limited (No. 97)
150, Saneopdanji-gil, Pungsan-eup
Andong-si, Gyeongsangbuk-do
Republic of Korea

WuXi Biologics Co., Ltd
108 Meiliang Road
Mashan
Binhu District
WuXi
Jiangsu 214092
China

Name and address of the manufacturer(s) responsible for batch release

AstraZeneca Nijmegen B.V.
Lagelandseweg 78
Nijmegen, 6545CG
Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to medical prescription.

• **Official batch release**

In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

- **Obligation to conduct post-authorisation measures**

The MAH shall complete, within the stated timeframe, the below measures:

Description	Due date
In order to elucidate the possible mechanisms of platelet activation after vaccination and to identify the possible triggers, the MAH should conduct and submit the final report for a non-clinical study to test in-vitro expression of the S protein of Vaxzevria.	7 July 2021
In order to ensure that all reported thrombotic events with thrombocytopenia and/or bleeding events are investigated by performing an in-depth exploration of platelet function in the interventional study in immunocompromised subjects, the MAH should submit the clinical study report, in accordance with a revised and agreed study protocol.	30 November 2023

E. SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION

This being a conditional marketing authorisation and pursuant to Article 14-a of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:

Description	Due date
In order to confirm the consistency of the active substance and finished product manufacturing process, the applicant should provide additional validation and comparability data and, introduce enhanced testing.	December 2021 with interim monthly updates beginning February 2021
In order to ensure consistent product quality, the applicant should provide additional information on stability of the active substance and finished product and review the finished product specifications following further manufacturing experience.	June 2022 with interim monthly updates beginning February 2021
In order to confirm the efficacy and safety of Vaxzevria, the MAH should submit the final Clinical Study Reports for the randomised, controlled studies COV001, COV002, COV003 and COV005.	31 May 2022
In order to confirm the efficacy and safety of Vaxzevria, the MAH should provide the final analysis from the pooled pivotal studies.	Final pooled analysis: 31 May 2022
In order to confirm the efficacy and safety of Vaxzevria in the elderly and subjects with underlying disease, the MAH should submit the overview and summaries of the final clinical study report for study D8110C00001.	Final CSR: 31 March 2024

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON - EIGHT-DOSE VIAL, PACK OF 10 VIALS

1. NAME OF THE MEDICINAL PRODUCT

Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])

2. STATEMENT OF ACTIVE SUBSTANCE(S)

One dose (0.5 mL) contains not less than 2.5×10^8 infectious units

Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein ChAdOx1-S

This medicine contains genetically modified organisms.

3. LIST OF EXCIPIENTS

Excipients: L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80 (E 433), ethanol, sucrose, sodium chloride, disodium edetate (dihydrate), water for injections.

See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Suspension for injection
10 multidose vials
(8 doses per vial - 0.5 mL per dose)
4 mL

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intramuscular use
Read the package leaflet before use.
For more information, scan here or visit www.azcovid-19.com
QR code to be included

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

Keep vials in outer carton in order to protect from light.

Do not freeze. Do not shake.

For information on the shelf life after first opening and additional storage information, see the package leaflet.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Dispose of in compliance with the local guidance for pharmaceutical waste.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/21/1529/001

10 multidose vials (8 doses per vial)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN
NN

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

VIAL LABEL - EIGHT-DOSE VIAL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Vaxzevria injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])

Intramuscular use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

Multidose vial (8 × 0.5 mL doses)
4 mL

6. OTHER

AstraZeneca

PARTICULARS TO APPEAR ON THE OUTER PACKAGING

CARTON - TEN-DOSE VIAL, PACK OF 10 VIALS

1. NAME OF THE MEDICINAL PRODUCT

Vaxzevria suspension for injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])

2. STATEMENT OF ACTIVE SUBSTANCE(S)

One dose (0.5 mL) contains not less than 2.5×10^8 infectious units

Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein ChAdOx1-S

This medicine contains genetically modified organisms.

3. LIST OF EXCIPIENTS

Excipients: L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80 (E 433), ethanol, sucrose, sodium chloride, disodium edetate (dihydrate), water for injections.

See leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

Suspension for injection
10 multidose vials
(10 doses per vial - 0.5 mL per dose)
5 mL

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intramuscular use
Read the package leaflet before use.
For more information, scan here or visit www.azcovid-19.com
QR code to be included

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator.

Keep vials in outer carton in order to protect from light.

Do not freeze. Do not shake.

For information on the shelf life after first opening and additional storage information, see the package leaflet.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Dispose of in compliance with the local guidance for pharmaceutical waste.

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

AstraZeneca AB
SE-151 85 Södertälje
Sweden

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/21/1529/002

10 multidose vials (10 doses per vial)

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Justification for not including Braille accepted.

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC

SN
NN

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

VIAL LABEL - TEN-DOSE VIAL

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Vaxzevria injection
COVID-19 Vaccine (ChAdOx1-S [recombinant])

Intramuscular use

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

Multidose vial (10 × 0.5 mL doses)
5 mL

6. OTHER

AstraZeneca

B. PACKAGE LEAFLET

Package leaflet: Information for the user

Vaxzevria suspension for injection COVID-19 Vaccine (ChAdOx1-S [recombinant])

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before the vaccine is given because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Vaxzevria is and what it is used for
2. What you need to know before you are given Vaxzevria
3. How Vaxzevria is given
4. Possible side effects
5. How to store Vaxzevria
6. Contents of the pack and other information

1. What Vaxzevria is and what it is used for

Vaxzevria is used for preventing COVID-19 caused by the SARS-CoV-2 virus.

Vaxzevria is given to adults aged 18 years and older.

The vaccine causes the immune system (the body's natural defences) to produce antibodies and specialised white blood cells that work against the virus, so giving protection against COVID-19. None of the ingredients in this vaccine can cause COVID-19.

2. What you need to know before you are given Vaxzevria

The vaccine must not be given:

- If you are allergic to the active substance or any of the other ingredients of this vaccine (listed in section 6).
- If you have had a blood clot occurring at the same time as having low levels of blood platelets (thrombosis with thrombocytopenia syndrome, TTS) after receiving Vaxzevria.
- If you have a previous diagnosis of capillary leak syndrome (a condition causing fluid leakage from small blood vessels).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given Vaxzevria:

- If you have ever had a severe allergic reaction after any other vaccine injection or after you were given Vaxzevria in the past;
- If you have ever fainted following any needle injection;
- If you have a severe infection with a high temperature (over 38°C). However, you can have your vaccination if you have a mild fever or upper airway infection like a cold;
- If you have a problem with bleeding or bruising, or if you are taking an anticoagulant medicine (to prevent blood clots);

- If your immune system does not work properly (immunodeficiency) or you are taking medicines that weaken the immune system (such as high-dose corticosteroids, immunosuppressants or cancer medicines);
- If you previously had Guillain-Barré syndrome (temporary loss of feeling and movement) after being given Vaxzevria.

If you are not sure if any of the above applies to you, talk to your doctor, pharmacist or nurse before you are given the vaccine.

As with any vaccine, the 2-dose vaccination course of Vaxzevria may not fully protect all those who receive it. It is not known how long you will be protected for.

Blood disorders

Very rare blood clots in combination with low level of blood platelets, in some cases together with bleeding, has been observed following vaccination with Vaxzevria. This included some severe cases with blood clots in different or unusual locations (e.g. brain, bowel, liver, spleen) and excessive clotting or bleeding throughout the body. The majority of these cases occurred within the first three weeks following vaccination. Some cases had a fatal outcome.

Very low levels of blood platelets (immune thrombocytopenia), that can be associated with bleeding, have been reported very rarely, usually within the first four weeks following vaccination with Vaxzevria.

Seek immediate medical attention if you develop shortness of breath, chest pain, leg swelling, leg pain or persistent abdominal pain following vaccination (see section 4).

Also, seek immediate medical attention if you experience after a few days following vaccination severe or persistent headaches, blurred vision, confusion or seizures (fits) after vaccination, or experience unexplained bleeding or skin bruising or pinpoint round spots beyond the site of vaccination which appears after a few days (see section 4).

Capillary leak syndrome

Very rare cases of capillary leak syndrome (CLS) have been reported following vaccination with Vaxzevria. Some affected patients had a previous diagnosis of CLS. CLS is a serious, potentially fatal condition causing fluid leakage from small blood vessels (capillaries) resulting in rapid swelling of the arms and legs, sudden weight gain and feeling faint (low blood pressure). Seek immediate medical attention if you develop these symptoms in the days following vaccination.

Neurological events

Seek immediate medical attention if you develop weakness and paralysis in the extremities that can progress to the chest and face (Guillain-Barré syndrome). This has been reported very rarely after vaccination with Vaxzevria.

Children and adolescents

Vaxzevria is not recommended for children aged below 18 years. Currently there is not enough information available on the use of Vaxzevria in children and adolescents younger than 18 years of age.

Other medicines and Vaxzevria

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take, any other medicines or vaccines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before you receive this vaccine.

Driving and using machines

Some of the side effects of Vaxzevria listed in section 4 (Possible side effects) may temporarily reduce your ability to drive and use machines. If you feel unwell after vaccination, do not drive or use machines. Wait until any effects of the vaccine have worn off before you drive or use machines.

Vaxzevria contains sodium and alcohol (ethanol)

This medicine contains less than 1 mmol sodium (23 mg) per 0.5 mL dose, that is to say essentially 'sodium-free'.

This medicine contains 2 mg of alcohol (ethanol) per 0.5 mL dose. The small amount of alcohol in this medicine will not have any noticeable effects.

3. How Vaxzevria is given

Vaxzevria is given as an injection of 0.5 mL into a muscle (usually in the upper arm).

During and after each injection of the vaccine, your doctor, pharmacist or nurse will watch over you for around 15 minutes to monitor for signs of an allergic reaction.

You will receive 2 injections of Vaxzevria. The second injection can be given between 4 and 12 weeks after the first injection. You will be told when you need to return for your second injection.

When Vaxzevria is given for the first injection, the second injection to complete the vaccination course should also be with Vaxzevria.

If you miss an appointment for your second injection of Vaxzevria

If you forget to go back at the scheduled time, ask your doctor, pharmacist or nurse for advice. It is important that you return for your second injection of Vaxzevria. If you miss a scheduled injection, you may not be fully protected against COVID-19.

4. Possible side effects

Like all medicines, this vaccine can cause side effects, although not everybody gets them.

In clinical studies, most side effects were mild to moderate in nature and resolved within a few days. Fewer side effects were reported after the second dose.

After vaccination, you may have more than one side effect at the same time (for example, muscle/joint aches, headaches, chills and generally feeling unwell). If any of your symptoms are persistent, please seek advice from your doctor, pharmacist or nurse.

Blood clots in combination with low levels of blood platelets (thrombosis with thrombocytopenia syndrome, TTS) have been reported very rarely, see section 2.

Get medical attention immediately if within three weeks of vaccination you get any of the following symptoms:

- experience a severe or persistent headache, blurred vision, confusion or seizures (fits)
- develop shortness of breath, chest pain, leg swelling, leg pain or persistent abdominal pain
- notice unusual skin bruising or pinpoint round spots beyond the site of vaccination

Get urgent medical attention if you get symptoms of a severe allergic reaction. Such reactions may include a combination of any of the following symptoms:

- feeling faint or light-headed
- changes in your heartbeat
- shortness of breath
- wheezing
- swelling of your lips, face, or throat

- hives or rash
- nausea or vomiting
- stomach pain.

The following side effects may occur with Vaxzevria:

Very Common (may affect more than 1 in 10 people)

- tenderness, pain, warmth, itching, or bruising where the injection is given
- feeling tired (fatigue) or generally feeling unwell
- chills or feeling feverish
- headache
- feeling sick (nausea)
- joint pain or muscle ache

Common (may affect up to 1 in 10 people)

- swelling or redness where the injection is given
- fever ($\geq 38^{\circ}\text{C}$)
- being sick (vomiting) or diarrhoea
- mild and transient decreased level of blood platelets (laboratory findings)
- pain in legs or arms
- flu-like symptoms, such as high temperature, sore throat, runny nose, cough and chills
- physical weakness or lack of energy

Uncommon (may affect up to 1 in 100 people)

- sleepiness, feeling dizzy, or deep unresponsiveness and inactivity
- abdominal pain or decreased appetite
- enlarged lymph nodes
- excessive sweating, itchy skin, rash or hives
- muscle spasms

Rare (may affect up to 1 in 1,000 people)

- one-sided facial drooping

Very Rare (may affect up to 1 in 10,000 people)

- blood clots often in unusual locations (e.g. brain, bowel, liver, spleen) in combination with low level of blood platelets
- serious nerve inflammation, which may cause paralysis and difficulty breathing (Guillain-Barré syndrome [GBS])

Not known (cannot be estimated from the available data)

- severe allergic reaction (anaphylaxis)
- hypersensitivity
- rapid swelling under the skin in areas such as the face, lips, mouth and throat (which may cause difficulty in swallowing or breathing)
- capillary leak syndrome (a condition causing fluid leakage from small blood vessels)
- very low levels of blood platelets (immune thrombocytopenia) that can be associated with bleeding (see section 2, Blood disorders)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Vaxzevria

Keep this medicine out of the sight and reach of children.

Your doctor, pharmacist or nurse is responsible for storing this vaccine and disposing of any unused product correctly. The following information about storage, expiry, use and handling as well as disposal is intended for healthcare professionals.

Do not use this vaccine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C).

Do not freeze.

Keep vials in outer carton in order to protect from light.

From the time of vial opening (first needle puncture) use within 6 hours when stored at temperatures up to 30°C. After this time, the vial must be discarded. Do not return it to the refrigerator.

Alternatively, an opened vial may be stored in a refrigerator (2°C – 8°C) for a maximum of 48 hours if it is immediately returned to the refrigerator following each puncture.

Discard the vial if the suspension is discoloured or particles are observed. Do not shake.

6. Contents of the pack and other information

What Vaxzevria contains

One dose (0.5 mL) contains:

Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein ChAdOx1-S*, not less than 2.5×10^8 infectious units

*Produced in genetically modified human embryonic kidney (HEK) 293 cells and by recombinant DNA technology.

This product contains genetically modified organisms (GMOs).

The other excipients are L-histidine, L-histidine hydrochloride monohydrate, magnesium chloride hexahydrate, polysorbate 80 (E 433), sucrose, disodium edetate (dihydrate), water for injections (see section 2 “Vaxzevria contains sodium and alcohol”).

What Vaxzevria looks like and contents of the pack

Suspension for injection (injection). The suspension is colourless to slightly brown, clear to slightly opaque.

Pack sizes:

- 8-dose multidose vial (4 mL) with stopper (elastomeric with aluminium overseal) in a pack of 10 vials. Each vial contains 8 doses of 0.5 mL.
- 10-dose multidose vial (5 mL) with stopper (elastomeric with aluminium overseal) in a pack of 10 vials. Each vial contains 10 doses of 0.5 mL.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

AstraZeneca AB
SE-151 85 Södertälje
Sweden

Manufacturer

AstraZeneca Nijmegen B.V.
Lagelandseweg 78

Nijmegen, 6545CG
Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

AstraZeneca S.A./N.V.
Tel: +32 2 808 53 06

България

АстраЗенека България ЕООД
Тел.: +359 (2) 90 60 798

Česká republika

AstraZeneca Czech Republic s.r.o.
Tel: +420 228 882 054

Danmark

AstraZeneca A/S
Tlf: +45 89 87 04 78

Deutschland

AstraZeneca GmbH
Tel: 0800 22 88 660 (gebührenfrei)

Eesti

AstraZeneca
Tel: +372 6549 600

Ελλάδα

AstraZeneca A.E.
Τηλ: +30 211 1983792

España

AstraZeneca Farmacéutica Spain, S.A.
Tel: +34 93 220 20 14

France

AstraZeneca
Tél: 0 800 08 92 44 (numéro vert)

Hrvatska

AstraZeneca d.o.o.
Tel: +385 1 4628 000

Ireland

AstraZeneca Pharmaceuticals (Ireland) DAC
Tel: 1800 812456 (toll free)

Ísland

Vistor hf.
Sími: +354 519 3643

Lietuva

UAB AstraZeneca Lietuva
Tel: +370 5 2141423

Luxembourg/Luxemburg

AstraZeneca S.A./N.V.
Tél/Tel: +352 2 7863166

Magyarország

AstraZeneca Kft.
Tel.: +36 80 180 007

Malta

Associated Drug Co. Ltd
Tel: +356 2277 8134

Nederland

AstraZeneca BV
Tel: 0800 70 11 (gratis)
+31 79 363 2222

Norge

AstraZeneca AS
Tlf: +47 23 96 23 13

Österreich

AstraZeneca Österreich GmbH
Tel: +43 1 711 31 0

Polska

AstraZeneca Pharma Poland Sp. z o.o.
Tel.: +48 22 104 60 80

Portugal

AstraZeneca Produtos Farmacêuticos, Lda.
Tel: +351 30 880 17 68

România

AstraZeneca Pharma SRL
Tel: +40 31 630 03 18

Slovenija

AstraZeneca UK Limited
Tel: +386 1 60 03 197

Slovenská republika

AstraZeneca AB, o.z.
Tel: +421 2 3321 5491

Italia

AstraZeneca S.p.A.
Tel: +39 02 9801 4221

Suomi/Finland

AstraZeneca Oy
Puh/Tel: +358 94 24 55072

Κύπρος

Αλέκτωρ Φαρμακευτική Λτδ
Τηλ: +357 22090050

Sverige

AstraZeneca AB
Tel: +46 3 130 11 892

Latvija

SIA AstraZeneca Latvija
Tel: +371 68688132

United Kingdom (Northern Ireland)

AstraZeneca UK Ltd
Tel: +44 8000 541 028

This leaflet was last revised in

This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.

The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.

Other sources of information

Scan the QR code with a mobile device to get **this information in different languages**.



www.azcovid-19.com

Detailed information on this medicine is available on the European Medicines Agency web site:
<http://www.ema.europa.eu>

This leaflet is available in all EU/EEA languages on the European Medicines Agency website.

The following information is intended **for healthcare professionals only**:

For storage and disposal, see section 5 “How to store Vaxzevria”.

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Handling instructions and administration

This vaccine should be handled by a healthcare professional using aseptic technique to ensure the sterility of each dose.

The vaccine should be inspected visually for particulate matter and discolouration prior to administration. Vaxzevria is a colourless to slightly brown, clear to slightly opaque suspension.

Discard the vial if the suspension is discoloured or visible particles are observed. Do not shake. Do not dilute the suspension.

The vaccine should not be mixed in the same syringe with any other vaccines or medicinal products.

The Vaxzevria vaccination course consists of two separate doses of 0.5 mL each. The second dose should be administered between 4 and 12 weeks after the first dose. Individuals who have received the first dose of Vaxzevria should receive the second dose of the same vaccine to complete the vaccination course.

Each vaccine dose of 0.5 mL is withdrawn into a syringe for injection to be administered intramuscularly, preferably in the deltoid muscle of the upper arm. Use a new needle for administration, when possible.

It is normal for liquid to remain in the vial after withdrawing the final dose. An additional overfill is included in each vial to ensure that 8 doses (vial of 4 mL) or 10 doses (vial of 5 mL) of 0.5 mL can be delivered. Do not pool excess vaccine from multiple vials. Discard any unused vaccine.

Disposal

Any unused vaccine or waste material should be disposed of in compliance with the local guidance for pharmaceutical waste. Potential spills should be disinfected with agents with viricidal activity against adenovirus.